

1. Company details

Name of entity:	Biome Australia Limited
ABN:	51 627 364 014
Reporting period:	For the half-year ended 31 December 2025
Previous period:	For the half-year ended 31 December 2024

2. Results for announcement to the market

			\$
Revenues from ordinary activities	up	39.9% to	12,399,653
Profit from ordinary activities after tax attributable to the owners of Biome Australia Limited	up	171.5% to	1,176,646
Profit for the half-year attributable to the owners of Biome Australia Limited	up	171.5% to	1,176,646

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The profit for the consolidated entity after providing for income tax amounted to \$1,176,646 (31 December 2024: \$433,395).

Financial Performance

Revenue for the half year increased 40% to \$12.40m (1H25: \$8.86m), driven by continued momentum across Biome's Activated Probiotics range and recently launched Activated Therapeutics. Gross margin remained strong at 61.1% (1H25: 61.0%).

Net profit after tax for the period was \$1.18m (1H25: \$0.43m), a 172% increase on the prior corresponding period. Sales and marketing expenditure increased to \$4.70m (1H25: \$3.2m), predominantly reflecting investment in sales team capability, sales-related activities and distribution costs associated with wholesale partnerships, to support the Company's growth domestically and internationally. Basic earnings per share increased to 0.53 cents (1H25: 0.20 cents). The Company has now delivered eight consecutive quarters of positive EBITDA.

Community pharmacy remains Biome's largest distribution channel, with the practitioner market also contributing meaningful growth. Internationally, the Company continues to expand, with early-stage operations in Canada showing promising traction alongside growing presence in Ireland, the United Kingdom and New Zealand.

Q2 FY26 revenue of \$6.48m represents an annualised run rate of approximately \$25.92m exiting the half.

Financial Position

The Company generated operating cash inflow of \$2.09m (1H25: outflow of \$1.12m), a \$3.21m turnaround on the prior corresponding period. Cash receipts from customers increased 62% to \$13.35m (1H25: \$8.22m), outpacing revenue growth and reflecting improved collections and working capital management.

Borrowings reduced to \$1.50m from \$2.91m at 30 June 2025, reflecting \$1.41m in net debt repayment during the half under the Company's restructured NAB facility.

The Company held \$3.36m in cash at 31 December 2025, with total current assets of \$10.99m and net assets of \$6.06m.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	2.63	2.06

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

11. Attachments

Details of attachments (if any):

The Interim Report of Biome Australia Limited for the half-year ended 31 December 2025 is attached.

12. Signed

Signed 

Mr Geoffrey Sam OAM
Chairman

Date: 20 February 2026

Biome Australia Limited

ABN 51 627 364 014

Interim Report - 31 December 2025

Directors	Geoffrey Sam OAM (Chairman) Blair William Brabin Vega Norfolk (Managing Director) Dominique Gayle Fisher AM (Independent Non-Executive Director)
Company secretary	George Lazarou
Chief financial officer	Lauren Dwyer - appointed 2 February 2026 Douglas Chee Yong Loh - resigned 2 February 2026
Registered office	192-194 Johnston Street Collingwood Victoria 3066 Phone: +61 3 9017 5800
Principal place of business	192-194 Johnston Street Collingwood Victoria 3066
Share register	Automic Pty Ltd 477 Collins Street Melbourne Victoria 3000 Phone: 1300 288 664
Auditor	MVAB Assurance Level 5, North Tower 485 La Trobe Street Melbourne VIC 3000
Stock exchange listing	Biome Australia Limited shares are listed on the Australian Securities Exchange (ASX code: BIO)
Website	www.biomeaustralia.com

Directors' report	3
Auditor's independence declaration	5
Statement of profit or loss and other comprehensive income	6
Statement of financial position	7
Statement of changes in equity	8
Statement of cash flows	9
Notes to the financial statements	10
Directors' declaration	14
Independent auditor's review report to the members of Biome Australia Limited	15

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Biome Australia Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2025.

Directors

The following persons were directors of Biome Australia Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Geoffrey Sam OAM (Chairman)
Blair William Brabin Vega Norfolk (Managing Director)
Dominique Gayle Fisher AM (Independent Non-Executive Director)

Principal activities

The principal continuing activities of the Group during the financial half-year were developing, manufacturing and distributing innovative evidence-based products linking the gut and human health through the Group owned brands:

- Activated Probiotics, a first-of-its-kind range of clinically-backed precision probiotics; and
- Activated Therapeutics, a range of targeted therapeutics formulated with clinically-validated natural ingredients.

Review of operations

The profit for the consolidated entity after providing for income tax amounted to \$1,176,646 (31 December 2024: \$433,395).

The gain for the consolidated entity after providing for income tax amounted to \$1,176,646 (31 December 2023: \$433,395).

Revenue for the half year increased 40% to \$12.4m (1H25: \$8.86m), driven by continued momentum across Biome's Activated Probiotics range and recently launched Activated Therapeutics. Gross margin remained strong at 61.1% (1H25: 61.0%).

Net profit after tax for the period was \$1.18m (1H25: \$0.43m), a 172% increase on the prior corresponding period. Sales and marketing expenditure increased to \$4.7m (1H25: \$3.2m), predominantly reflecting investment in sales team capability, sales-related activities and distribution costs associated with wholesale partnerships, to support the Company's growth domestically and internationally. Basic earnings per share increased to 0.53 cents (1H25: 0.20 cents). The Company has now delivered eight consecutive quarters of positive EBITDA.

Community pharmacy remains Biome's largest distribution channel, with the practitioner market also contributing meaningful growth. Internationally, the Company continues to expand, with early-stage operations in Canada showing promising traction alongside growing presence in Ireland, the United Kingdom and New Zealand.

Q2 FY26 revenue of \$6.48m represents an annualised run rate of approximately \$25.9m exiting the half.

Financial Position

The Company generated operating cash inflow of \$2.09m (1H25: outflow of \$1.12m), a \$3.21m turnaround on the prior corresponding period. Cash receipts from customers increased 62% to \$13.3m (1H25: \$8.2m), outpacing revenue growth and reflecting improved collections and working capital management.

Borrowings reduced to \$1.5m from \$2.9m at 30 June 2025, reflecting \$1.4m in net debt repayment during the half under the Company's restructured NAB facility.

The Company held \$3.36m in cash at 31 December 2025, with total current assets of \$10.99m and net assets of \$6.1m. Q2 FY26 revenue of \$6.48m represents an annualised run rate of approximately \$25.9m exiting the half.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the consolidated entity during the financial half-year.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors

A handwritten signature in black ink, appearing to be 'G. Sam', written over a horizontal line.

Mr Geoffrey Sam OAM
Chairman

20 February 2026


**AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF BIOME AUSTRALIA LIMITED**

I declare that, to the best of my knowledge and belief, during the half-year ended 31 December 2025 there have been:

- (i) no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- (ii) No contraventions of any applicable code of professional conduct in relation to the review.

MVAB Assurance

MVAB ASSURANCE
Chartered Accountants



SAM CLARINGBOLD
Partner

Signed at Melbourne this 20th day of February 2026

Biome Australia Limited
Statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2025

		Consolidated	
	Note	31 December 2025	31 December 2024
		\$	\$
Revenue			
Sales revenue		12,399,653	8,864,264
Cost of goods sold		(4,819,025)	(3,455,216)
Gross profit		7,580,628	5,409,048
Other income	5	656,670	437,128
Expenses			
Sales and marketing expenses		(4,703,423)	(3,213,700)
Corporate and administrative expenses		(1,905,531)	(1,918,945)
Occupancy costs		(147,913)	(50,546)
Finance expenses		(112,734)	(86,593)
Depreciation and amortisation expense		(146,150)	(119,340)
Other expenses		(44,901)	(23,657)
Profit before income tax expense		1,176,646	433,395
Income tax expense		-	-
Profit after income tax expense for the half-year attributable to the owners of Biome Australia Limited		1,176,646	433,395
Other comprehensive income for the half-year, net of tax		-	-
Total comprehensive income for the half-year attributable to the owners of Biome Australia Limited		1,176,646	433,395
		Cents	Cents
Basic earnings per share	13	0.53	0.20
Diluted earnings per share	13	0.52	0.19

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Biome Australia Limited
Statement of financial position
As at 31 December 2025

		Consolidated	
	Note	31 December 2025	30 June 2025
		\$	\$
Assets			
Current assets			
Cash and cash equivalents		3,355,947	2,746,416
Trade and other receivables		3,310,691	4,327,593
Inventories	6	3,892,150	4,111,914
Other assets		430,354	255,306
Total current assets		<u>10,989,142</u>	<u>11,441,229</u>
Non-current assets			
Property, plant and equipment		188,130	224,585
Right-of-use assets	7	890,387	138,887
Intangibles		240,981	163,239
Total non-current assets		<u>1,319,498</u>	<u>526,711</u>
Total assets		<u>12,308,640</u>	<u>11,967,940</u>
Liabilities			
Current liabilities			
Trade and other payables		2,883,027	3,600,102
Borrowings	8	1,500,000	2,905,413
Lease liabilities		236,234	116,833
Employee benefits		873,673	557,676
Total current liabilities		<u>5,492,934</u>	<u>7,180,024</u>
Non-current liabilities			
Lease liabilities		694,891	50,979
Employee benefits		61,570	61,570
Total non-current liabilities		<u>756,461</u>	<u>112,549</u>
Total liabilities		<u>6,249,395</u>	<u>7,292,573</u>
Net assets		<u>6,059,245</u>	<u>4,675,367</u>
Equity			
Issued capital	9	23,444,775	23,323,346
Share options reserve		492,421	406,618
Accumulated losses		(17,877,951)	(19,054,597)
Total equity		<u>6,059,245</u>	<u>4,675,367</u>

The above statement of financial position should be read in conjunction with the accompanying notes

Biome Australia Limited
Statement of changes in equity
For the half-year ended 31 December 2025

Consolidated	Ordinary shares \$	Option reserve \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2024	21,727,165	444,212	(19,267,849)	2,903,528
Profit after income tax expense for the half-year	-	-	433,395	433,395
Other comprehensive income for the half-year, net of tax	-	-	-	-
Total comprehensive income for the half-year	-	-	433,395	433,395
<i>Transactions with owners in their capacity as owners:</i>				
Share-based payments	-	96,480	-	96,480
Exercise of options	1,325,217	(225,655)	-	1,099,562
Balance at 31 December 2024	<u>23,052,382</u>	<u>315,037</u>	<u>(18,834,454)</u>	<u>4,532,965</u>
Consolidated	Ordinary shares \$	Option reserve \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2025	23,323,346	406,618	(19,054,597)	4,675,367
Profit after income tax expense for the half-year	-	-	1,176,646	1,176,646
Other comprehensive income for the half-year, net of tax	-	-	-	-
Total comprehensive income for the half-year	-	-	1,176,646	1,176,646
<i>Transactions with owners in their capacity as owners:</i>				
Share-based payments (note 14)	121,429	85,803	-	207,232
Balance at 31 December 2025	<u>23,444,775</u>	<u>492,421</u>	<u>(17,877,951)</u>	<u>6,059,245</u>

The above statement of changes in equity should be read in conjunction with the accompanying notes

Biome Australia Limited
Statement of cash flows
For the half-year ended 31 December 2025

	Consolidated	
	31 December 2025	31 December 2024
Note	\$	\$
Cash flows from operating activities		
Receipts from customers (inclusive of GST)	13,347,411	8,223,345
Payments to suppliers and employees (inclusive of GST)	(11,831,396)	(9,362,347)
Other government grants received	656,644	53,084
Interest received	26	46,877
Interest and finance costs paid	(86,784)	(85,559)
Net cash from/(used in) operating activities	2,085,901	(1,124,600)
Cash flows from investing activities		
Payments for property, plant and equipment	(43,225)	(45,262)
Payments for intellectual property	(77,742)	(135,606)
Net cash used in investing activities	(120,967)	(180,868)
Cash flows from financing activities		
Proceeds from issue of shares	9 108,428	1,099,562
Payments for lease liabilities	(58,418)	(52,607)
Repayment of borrowings	(1,405,413)	(23,000)
Net cash from/(used in) financing activities	(1,355,403)	1,023,955
Net increase/(decrease) in cash and cash equivalents	609,531	(281,513)
Cash and cash equivalents at the beginning of the financial half-year	2,746,416	2,868,526
Cash and cash equivalents at the end of the financial half-year	3,355,947	2,587,013

The above statement of cash flows should be read in conjunction with the accompanying notes

Note 1. General information

The financial statements cover Biome Australia Limited as a consolidated entity consisting of Biome Australia Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Biome Australia Limited's functional and presentation currency.

Biome Australia Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

Registered office	Principal place of business
192-194 Johnston Street Collingwood Victoria 3066	192-194 Johnston Street Collingwood Victoria 3066

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 17 February 2026.

Note 2. Material accounting policies

These general purpose financial statements for the interim half-year reporting period ended 31 December 2025 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2025 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Note 3. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Share-based payment transactions

The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Binomial or Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Note 3. Critical accounting judgements, estimates and assumptions (continued)

Allowance for expected credit losses

The allowance for expected credit losses assessment requires a degree of estimation and judgement. It is based on the lifetime expected credit loss, grouped based on days overdue, and makes assumptions to allocate an overall expected credit loss rate for each group. These assumptions include recent sales experience and historical collection rates.

Provision for impairment of inventories

The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventories and other factors that affect inventory obsolescence.

Note 4. Operating segments

Identification of reportable operating segments

The company is organised into one operating segments: researching, developing, manufacturing and distributing innovative evidence-based products linking the gut and human health. This operating segment is based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

Note 5. Other income

	Consolidated	
	31 December 2025	31 December 2024
	\$	\$
Government grants	-	53,084
Interest	26	46,877
R & D rebate	656,644	337,167
Other income	<u>656,670</u>	<u>437,128</u>

Note 6. Current assets - inventories

	Consolidated	
	31 December 2025	30 June 2025
	\$	\$
Raw materials - at cost	109,702	490,958
Finished goods - at cost	3,805,958	3,666,706
Provision for stock impairment	(23,510)	(45,750)
	<u>3,892,150</u>	<u>4,111,914</u>

Note 7. Non-current assets - right-of-use assets

	Consolidated	
	31 December 2025	30 June 2025
	\$	\$
Land and buildings - right-of-use	1,308,152	490,189
Less: Accumulated depreciation	(417,765)	(351,302)
	<u>890,387</u>	<u>138,887</u>

Note 8. Current liabilities - borrowings

	Consolidated	
	31 December 2025	30 June 2025
	\$	\$
Loan - NAB Trade Finance	1,080,000	1,300,000
Loan - NAB Invoice Finance	420,000	1,605,413
	<u>1,500,000</u>	<u>2,905,413</u>

Note 9. Equity - issued capital

	Consolidated			
	31 December 2025	30 June 2025	31 December 2025	30 June 2025
	Shares	Shares	\$	\$
Ordinary shares - fully paid	<u>222,609,231</u>	<u>220,609,231</u>	<u>23,444,775</u>	<u>23,323,346</u>

Movements in ordinary share capital

Details	Date	Shares	Issue price	\$
Balance	1 July 2025	220,609,231		23,323,346
Shares issued under Employee Incentive Scheme pursuant to the Loan Funded Share Plan (LFSP)	2 December 2025	2,000,000	\$0.40	35,628
Transfer from share options reserve		-	\$0.00	85,801
Balance	31 December 2025	<u>222,609,231</u>		<u>23,444,775</u>

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Note 10. Equity - dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

Note 11. Contingent liabilities

The Managing Director is entitled to a long term incentive (LTI) should specified consolidated revenue targets be delivered over a three year period from 1 July 2024 to 30 June 2027. The maximum liability under this plan is \$1,000,000 to be earned over a three-year period up to and including the year ending 30 June 2027. The Company intends to start accruing this liability in its accounts once the minimum 80% LTI target of \$60.0m cumulative sales is met prior to 30 June 2027.

June 25: The Chief Financial Officer (CFO)'s \$250,000 LTI reported as a contingent liability at June 2025 has been expensed in the financial half year period as final the service period condition has been satisfied.

Note 12. Events after the reporting period

On 2 February 2026, Ms Lauren Dwyer was appointed Chief Financial Officer replacing Douglas Loh who has retired.

No other matter or circumstance has arisen since 31 December 2025 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Note 13. Earnings per share

	Consolidated	
	31 December 2025	31 December 2024
	\$	\$
Profit after income tax attributable to the owners of Biome Australia Limited	1,176,646	433,395
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	220,926,171	217,672,553
Adjustments for calculation of diluted earnings per share:		
Options over ordinary shares	5,375,000	7,024,752
Weighted average number of ordinary shares used in calculating diluted earnings per share	226,301,171	224,697,305
	Cents	Cents
Basic earnings per share	0.53	0.20
Diluted earnings per share	0.52	0.19

Note 14. Share-based payments

During the current financial half year period, the company issued 2,000,000 ordinary shares, vesting over 3 years under its (LFSP) Loan Funded Share Plan with a 10-year non-recourse loan term. The equity value of these shares will be recognised and credited to the Share Capital account as and when the loans are repaid.

The Company has previously issued ordinary shares under its Employee Incentive Scheme. Shares issued under its LFSP typically vest between one to three years from the date of issue. During the current financial half year period, 766,620 LFSP shares were repaid in full. The equity value of these shares were credited to the Share Capital account.

(*) Valuation of LFSP shares is determined by using industry standard Black-Scholes-Merton (BSM) model taking into account the terms and conditions upon which instruments are issued and are amortised as share-based payments expense over the vesting period.

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2025 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors



Mr Geoffrey Sam OAM
Chairman

20 February 2026

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF BIOME AUSTRALIA LIMITED
ABN 51 627 364 014**Report on the Half-year Financial Report****Conclusion**

We have reviewed the accompanying half-year financial report of Biome Australia Limited, which comprises the consolidated condensed statement of financial position as at 31 December 2025, the consolidated condensed statement of profit or loss, the consolidated condensed statement of comprehensive income, the consolidated condensed statement of changes in equity and the consolidated condensed statement of cash flows for the half-year ended on that date, notes comprising a summary of material accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Biome Australia Limited is not in accordance with the Corporations Act 2001, including:

- (i) giving a true and fair view of Biome Australia Limited's financial position as at 31 December 2025 and of its performance for the half-year ended on that date; and
- (ii) complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations 2001.

Directors' Responsibility for the Half-year Financial Report

The directors of Biome Australia Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410: Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of Biome Australia Limited's financial position as at 31 December 2025 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of Biome Australia Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.



MVAB ASSURANCE
Chartered Accountants



SAM CLARINGBOLD
Partner

Signed at Melbourne this 20th day of February 2026

Melbourne

Level 5 North Tower
485 La Trobe Street
Melbourne, Vic 3000

T. +61 9642 8000
E. info@mvabennett.com.au